View Older Stories View More Recent Stories

Nov 3, 2025 04:00PM U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Nov 3, 2025 04:00PM /C O R R E C T I O N -- UCB/
Oct 29, 2025 12:00PM UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Oct 29, 2025 07:00AM UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
Oct 25, 2025 11:00AM BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Oct 14, 2025 07:10AM Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior
Oct 13, 2025 07:00AM Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Aug 29, 2025 01:15AM UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 5, 2025 08:00AM UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
Jul 8, 2025 07:00AM UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
Jun 27, 2025 07:00AM UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Jun 20, 2025 07:00AM UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
Jun 17, 2025 08:22AM Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
Jun 12, 2025 12:30PM UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Jun 11, 2025 12:16PM BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
May 19, 2025 12:30PM UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
Apr 3, 2025 07:00AM UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Mar 19, 2025 07:00AM New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Mar 12, 2025 01:54PM Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
Mar 7, 2025 08:00AM BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Mar 7, 2025 08:00AM BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
Feb 27, 2025 07:00AM On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Jan 16, 2025 07:00AM UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Jan 9, 2025 08:00AM UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Dec 6, 2024 12:00PM UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
Nov 29, 2024 08:00PM CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
Nov 26, 2024 07:00AM UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov 20, 2024 07:00AM UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
Nov 14, 2024 12:46PM New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Oct 11, 2024 07:00AM UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) S
Sep 30, 2024 07:00AM UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
Sep 27, 2024 07:00AM UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
Sep 25, 2024 07:00AM UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Sep 23, 2024 07:00AM UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Aug 16, 2024 11:01AM UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")
Jul 29, 2024 12:00PM UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
Jun 24, 2024 07:00AM FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia
Jun 20, 2024 08:00AM UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
Jun 13, 2024 07:00AM New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
Jun 12, 2024 07:00AM UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
May 23, 2024 07:00AM UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
Apr 12, 2024 07:00AM UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
Apr 10, 2024 08:00AM UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
Apr 4, 2024 07:00AM FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
Mar 9, 2024 12:00PM First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Mar 8, 2024 12:00PM BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
Feb 28, 2024 07:03AM UCB on Growth Path for a Decade Plus
Jan 3, 2024 07:00AM ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positiv
Dec 2, 2023 07:00AM UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
Dec 1, 2023 07:00AM UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
View More Recent Stories View Older Stories